Rosamicin--a new drug for the treatment of bacterial prostatitis.

Antimicrobial Agents and Chemotherapy
A BaumuellerP O Madsen

Abstract

Rosamicin, a new macrolide substance, was investigated in dogs and humans with regard to its usefulness for the treatment of bacterial prostatitis and compared with the well-known macrolide erythromycin. In dogs with normal and experimentally infected prostates, concentration ratios for rosamicin in prostatic secretion, interstitial fluid (obtained from implanted tissue chambers), and tissue were significantly higher than for erythromycin. The difference was even more pronounced in human prostatic tissue, obtained by transurethral resection. With its broad spectrum against many common urinary pathogens, rosamicin seems to be a promising drug for the treatment of acute and chronic bacterial prostatitis.

References

Dec 30, 1975·Urological Research·H U EickenbergL Scharfenberger
Feb 1, 1976·Antimicrobial Agents and Chemotherapy·V L Sutter, S M Finegold
Nov 1, 1972·The Journal of Antibiotics·J A WaitzM J Weinstein
Nov 1, 1972·The Journal of Antibiotics·G H WagmanM J Weinstein
Mar 1, 1974·Antimicrobial Agents and Chemotherapy·C C Crowe, W E Sanders
Aug 1, 1972·Archives of Surgery·N G Waterman, L B Kastan

❮ Previous
Next ❯

Citations

Aug 1, 1978·Antimicrobial Agents and Chemotherapy·J R DiPersio, T L Krafczyk
Sep 1, 1978·Antimicrobial Agents and Chemotherapy·T F Smith, H E Washton
Nov 1, 1980·Antimicrobial Agents and Chemotherapy·C LinS Symchowicz
Jul 1, 1983·Antimicrobial Agents and Chemotherapy·R P SmithA L Baltch
May 1, 1986·Antimicrobial Agents and Chemotherapy·C C LinS Symchowicz
Sep 1, 1982·Urology·A M Ristuccia, B A Cunha
May 1, 1985·Urology·S M OrlandA J Wein
Aug 1, 1986·Journal of Clinical and Hospital Pharmacy·A C Lafong, P G Murphy
Jan 1, 1980·The Prostate·O S NielsenP O Madsen
Oct 1, 1981·Drug Intelligence & Clinical Pharmacy·N Massoud

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.